Butein
(Synonyms: 紫铆因; 2’,3,4,4’-tetrahydroxy Chalcone) 目录号 : GC10944A plant polyphenol
Cas No.:487-52-5
Sample solution is provided at 25 µL, 10mM.
Butein, a chalconoid has anti-oxidant effect, which has various pharmacological effects.
Reactive oxygen species (ROS), produced intracellularly through multiple mechanisms and depending on the cell and tissue types, mainly ROS NADPH oxidase (NOX) complexes in cell membranes, mitochondria, peroxisomes, and endoplasmic reticulum, via dental adhesive bleaching agents and pulpal disease, can cause oxidative stress. [1] ROS are formed as a natural product of the normal metabolism of oxygen and have important roles in cell signaling and homeostasis. However, during times of environmental stress, ROS levels can increase dramatically.[2] H2O2-induced cytotoxicity and production of ROS were blocked in the presence of butein, and these effects were dose dependent.Due to the dual role of ROS, both prooxidant and antioxidant-based anticancer agents have been developed.
Butein can induce the apoptosis in B16 melanoma cells and human promyelocytic leukemia cells, inhibit diabetes complications, and inhibit enzymes such as protein kinases and glutathione reductase. [3,4,5,6] Recently, Butein was isolated from R. verniciflua which suppress cellular damage from oxidation caused by H2O2 in HDP cells, through JNK–Nrf2/ARE-dependent HO-1 expression.[7] In addition, Butein attenuated VEGF and MMP-9 activities via the suppression of NF-kB activity by flow cytometric analysis and RT-PCR in vitro. Furthermore, Butein repressed the expression of VEGF and MMP-9 induced by treatment with tumor necrosis factor-ɑ and phorbol-12-myristate-13-acetate mainly through Electrophoretic mobility shift assay (EMSA) and Enzyme-linked immunosorbent assay (ELISA), resulting in an inhibition of cell growth, invasion and angiogenesis of prostate cancer .[8] Thus, Butein may be a promising therapeutic agent for the treatment of various dental diseases.
References:
1.Han D, Williams E, Cadenas E."Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space". Biochem. J. 2010, 353 (2): 411-6.
2.Devasagayam, TPA; Tilak JC; Boloor KK; Sane Ketaki S; Ghaskadbi Saroj S; Lele RD. "Free Radicals and Antioxidants in Human Health: Current Status and Future Prospects". Journal of Association of Physicians of India (JAPI), 2004, 52: 796.
3.S. Sogawa, Y. Nero, H. Ueda, T. Miki. Protective effects of hydroxychalcones on free radical-induced cell damage. Biol. Pharm. Bull., 1994, 251-256.
4.J.C. Lee, K.T. Lim, Y.S. Jang. Identification of Rhus verniciflua Stokes compounds that exhibit free radical scavenging and anti-apoptotic properties. Biochim. Biophys. Acta, 2002, 181-191.
5.S.M. Yu, Z.J. Cheng, S.C. Kuo. Endothelium-dependent relaxation of rat aorta by butein, a novel cyclic AMP-specific phosphodiesterase inhibitor. Eur. J. Pharmacol., 1995, 69-77.
6.K. Iwashita, M. Kobori, K. Yamaki, T. Tsushida. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci. Biotechnol. Biochem., 2000, 1813-1820.
7.Dong-Sung Lee.et al. Butein protects human dental pulp cells from hydrogen peroxide-induced oxidative toxicity via Nrf2 pathway-dependent heme oxygenase-1 expressions.Toxicology in Vitro, 2013, 874-881.
8.Dong-Oh Moona.et al. Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells. Toxicology in Vitro, 2010,24(7) ,1927-1934.
Cas No. | 487-52-5 | SDF | |
别名 | 紫铆因; 2’,3,4,4’-tetrahydroxy Chalcone | ||
化学名 | (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one | ||
Canonical SMILES | C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O | ||
分子式 | C15H12O5 | 分子量 | 272.25 |
溶解度 | ≥ 13.6mg/mL in DMSO | 储存条件 | Store at -20°C ,protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.6731 mL | 18.3655 mL | 36.7309 mL |
5 mM | 0.7346 mL | 3.6731 mL | 7.3462 mL |
10 mM | 0.3673 mL | 1.8365 mL | 3.6731 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet